Home › Funds › Nantahala Capital Management, LLC › IRD
Nantahala Capital Management, LLC position in IRD
OPUS GENETICS INC · Health Care
Nantahala Capital Management, LLC reported holding 4,569,528 shares of IRD (OPUS GENETICS INC) in its Q3 2026 13F filing — a position valued at US$22.1M, representing 1.02% of its reported portfolio and ranking #35 among its reported holdings. Nantahala Capital Management, LLC has disclosed IRD holdings in 7 of the last 7 reported quarters, going back to Q1 2025.
Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR
How Nantahala Capital Management, LLC's IRD position evolved
Nantahala Capital Management, LLC first disclosed a stake in IRD in Q1 2025 at 3,157,895 shares (US$3.1M). The position peaked in Q3 2026 at 4,569,528 shares, worth US$22.1M. Across 7 filings, Nantahala Capital Management, LLC increased the stake 4 time(s), trimmed it 1 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 4,569,528 shares valued at US$22.1M — an increase of 1,508,169 shares quarter over quarter.. Notable position changes include a 65% trim in Q1 2026 (shares fell 10% over the following quarter), a 82% increase in Q2 2026 (shares rose 18% over the following quarter), a 49% increase in Q3 2026 (shares fell 18% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2025 | 3.16M | $3.10M | New |
| Q2 2025 | 3.35M | $3.15M | Add |
| Q3 2025 | 3.35M | $5.52M | Hold |
| Q4 2025 | 4.78M | $9.61M | Add |
| Q1 2026 | 1.68M | $7.65M | Reduce |
| Q2 2026 | 3.06M | $12.58M | Add |
| Q3 2026 | 4.57M | $22.12M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About IRD and 13F data
IRD (OPUS GENETICS INC) is a Health Care company. 69 other funds we track also report a position in IRD — the largest reported positions include BIOS Capital Management, LP (US$17.83B), Caligan Partners LP (US$25.0M), Boxer Capital Management, LLC (US$11.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding IRD
- BIOS Capital Management, LP 3.68M sh · $17.83B · Q3 2026
- Caligan Partners LP 6.08M sh · $24.98M · Q2 2026
- Boxer Capital Management, LLC 2.81M sh · $11.57M · Q2 2026
- Trails Edge Capital Partners, LP 2.74M sh · $11.28M · Q2 2026
- GREAT POINT PARTNERS LLC 1.97M sh · $8.10M · Q2 2026
- Blue Owl Capital Holdings LP 969.61K sh · $4.69M · Q3 2026
- Opaleye Management Inc. 1.12M sh · $4.62M · Q2 2026
- Propel Bio Management, LLC 270.04K sh · $1.31M · Q3 2026
- Stonepine Capital Management, LLC 98.15K sh · $475.03K · Q3 2026
More on Nantahala Capital Management, LLC
FAQ
How long has Nantahala Capital Management, LLC held IRD?
Nantahala Capital Management, LLC has disclosed IRD holdings in 7 of the last 7 reported quarters, going back to Q1 2025.
What is Nantahala Capital Management, LLC's current position in IRD?
As of Q3 2026, Nantahala Capital Management, LLC holds 4.57M shares of IRD (OPUS GENETICS INC), valued at $22.12M, representing 1.02% of its reported portfolio and ranking #35.
Has Nantahala Capital Management, LLC been buying or selling IRD?
In the latest 13F filing (Q3 2026), Nantahala Capital Management, LLC increased its position in IRD. The position peaked in Q3 2026 at 4.57M shares.
Which other funds hold IRD?
Other major institutional holders of IRD include BIOS Capital Management, LP, Caligan Partners LP, Boxer Capital Management, LLC, among 69 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.